代谢组学谱揭示了吴茱萸汤对慢性非萎缩性胃炎患者的疗效。
Metabolomics Profiles Reveal the Efficacy of Wuzhuyu Decoction on Patients with Chronic Non-Atrophic Gastritis.
机构信息
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, People's Republic of China.
Department of Pharmacy, Chinese PLA General Hospital, Beijing, People's Republic of China.
出版信息
Drug Des Devel Ther. 2023 Nov 7;17:3269-3280. doi: 10.2147/DDDT.S428783. eCollection 2023.
OBJECTIVE
Chronic non-atrophic gastritis (CNAG) is a common clinical gastrointestinal disease with a long and recurrent course. In China, Wuzhuyu decoction (WZYD) has been used for centuries to treat gastrointestinal disorders. To unravel the efficacy and mechanism of WZYD for CNAG, a clinical study was conducted. And metabolomics was used to explore the mechanism of WZYD for CNAG patients.
METHODS
Twenty patients in total were recruited in this study (Nos. ChiCTR2200062296) and the protocol was approved by the Ethics Committee (Approval number: KY-2022-2-6-1) and complied with the Declaration of Helsinki. The formula granule of WZYD were assessed by UHPLC-QQQ-TOF to discern the main potential active compounds. The endoscopy evaluation and histopathological changes were detected as effective indicators. Serum samples from patients were used for metabolomics. Inflammatory factors in patients' serum were determined by ELISA. Metabolomics revealed a series of differential metabolites and signaling pathways.
RESULTS
WZYD was capable to prevent CNAG by ameliorating score of endoscopy evaluation including erosion, hemorrhage, as well as chronic inflammation and active chronic inflammation score after treatment were decreased. The results indicated that 10 core metabolic components were associated with the treatment of WZYD. Moreover, these metabolic components proved that pyrimidine metabolism and thiamine metabolism were critically responsible for CNAG. In addition, WZYD treatment effectively reduced serum levels of TNF-α, IL-10, and COX-2.
CONCLUSION
Altogether, WZYD can effectively alleviate CNAG by inhibiting inflammation and regulating related metabolic processes, which might be the molecular mechanism of WZYD treatment of CNAG. More studies are warranted to be conducted in this area.
TRIAL REGISTRATION
ChiCTR, ChiCTR2200062296. Registered 1 August 2022, https://www.chictr.org.cn/com/25/showprojen.aspx?proj=174027.
目的
慢性非萎缩性胃炎（CNAG）是一种常见的临床胃肠道疾病，具有病程长、反复发作的特点。在中国，吴茱萸汤（WZYD）已被用于治疗胃肠道疾病数百年。为了揭示 WZYD 治疗 CNAG 的疗效和机制，进行了一项临床研究。并采用代谢组学方法探讨 WZYD 治疗 CNAG 患者的作用机制。
方法
本研究共纳入 20 例患者（编号：ChiCTR2200062296），方案经伦理委员会批准（批准号：KY-2022-2-6-1），并符合赫尔辛基宣言。采用 UHPLC-QQQ-TOF 对 WZYD 配方颗粒进行评估，以识别主要潜在活性化合物。内窥镜评估和组织病理学变化被检测为有效指标。患者血清样本用于代谢组学分析。采用 ELISA 法测定患者血清中炎症因子。代谢组学揭示了一系列差异代谢物和信号通路。
结果
WZYD 可通过改善内窥镜评估评分来预防 CNAG，包括糜烂、出血以及治疗后慢性炎症和活动慢性炎症评分的降低。结果表明，10 种核心代谢成分与 WZYD 的治疗有关。此外，这些代谢成分表明嘧啶代谢和硫胺素代谢与 CNAG 密切相关。此外，WZYD 治疗可有效降低 TNF-α、IL-10 和 COX-2 血清水平。
结论
总之，WZYD 可通过抑制炎症和调节相关代谢过程有效缓解 CNAG，这可能是 WZYD 治疗 CNAG 的分子机制。需要在这一领域开展更多的研究。
试验注册
ChiCTR，ChiCTR2200062296。注册于 2022 年 8 月 1 日，https://www.chictr.org.cn/com/25/showprojen.aspx?proj=174027。
Zotero 插件